Takeda CEO Admits Error In Ads Touting Blopress For High Blood Pressure
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical CEO Yasuchika Hasegawa apologized and acknowledged during a news conference the company was guilty of "partially inappropriate" advertising of its Blopress (candesartan) blood-pressure drug.